Fuente: FierceBiotech In the world of clinical trials, missing the primary endpoint of a pivotal trial typically spells real trouble for a drug program. But for Valneva CEO Thomas Lingelbach, the regulatory future of the Pfizer-partner Lyme disease vaccine, VLA15, is very much “a matter of negotiation.”